In terms of molecular therapeutic approaches for gliomas, two therapeutic approaches are already standard of care for patients with gliomas harboring BRAF-V600E alterations and for patients with tuberous sclerosis and subependymal giant cell astrocytoma (SEGA). This evidence concerns the gene BRAF and subependymal giant cell astrocytoma.